The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...

CFD rigs are now outfitted with "mini blood banks" stocked with Type O blood, allowing them to perform blood transfusions in ...

R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS ...